title: Clinical symptoms and microbiological outcomes in tuberculosis treatment trials.
abstract: During a recent Food and Drug Administration workshop on clinical trials to evaluate new TB drugs, questions were raised regarding the use of bacteriologic endpoints such as treatment failure and relapse as measures of improvement in health status and long term outcome after treatment. FDA scientists asked how patients' clinical signs and symptoms changed during therapy, noting that while such information is usually collected during clinical trials, it is not often reported. We analyzed data from an international phase 3 TB treatment trial that included systematic assessments of symptoms. The percentage of subjects with self-reported symptoms at baseline ranged from 30% for dyspnea to 81% for cough, with 51% reporting fever. During therapy, fever, sweats, and dyspnea decreased most rapidly, with near resolution by the end of therapy. Chest pain and cough resolved more slowly; 13% of subjects reported cough at six months. Symptom resolution during treatment did not differ between those who relapsed and those who did not. Among those with microbiological relapse, symptoms returned with significant increases in the proportion with fever, cough, and chest pain. At the time of relapse, cough was the most frequent symptom, occurring in 75% of subjects who relapsed but only 12% of those who did not. Our data support the continued use of bacteriologic endpoints based on sputum culture as surrogate measures of the relief of symptoms, improvement in health status and favorable long term treatment outcome in TB drug trials.
authors.affiliation: Tuberculosis Research Unit, Department of Medicine, Case Western Reserve University, Cleveland, OH, USA. cmb148@case.edu
authors.forename: C M
authors.initials: CM
authors.lastname: Bark
authors.forename: R
authors.initials: R
authors.lastname: Dietze
authors.forename: A
authors.initials: A
authors.lastname: Okwera
authors.forename: M I
authors.initials: MI
authors.lastname: Quelapio
authors.forename: B A
authors.initials: BA
authors.lastname: Thiel
authors.forename: J L
authors.initials: JL
authors.lastname: Johnson
mesh_terms: D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D015415:Biomarkers; D001938:Brazil / Q000453:epidemiology; D002986:Clinical Trials as Topic; D003371:Cough / Q000453:epidemiology* / Q000382:microbiology; D004417:Dyspnea / Q000453:epidemiology* / Q000382:microbiology; D005260:Female; D005334:Fever / Q000453:epidemiology* / Q000382:microbiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010679:Philippines / Q000453:epidemiology; D012008:Recurrence; D017211:Treatment Failure; D014376:Tuberculosis / Q000188:drug therapy* / Q000453:epidemiology*; D014454:Uganda / Q000453:epidemiology; D014481:United States; D014486:United States Food and Drug Administration; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D015415:Biomarkers